Abstract
It was shown that in the model of dry eye syndrome (DES) in rabbits, if drug No. 5 was instilled in both eyes of animals at a dose of 0.05 mL/kg in 1:15 dilution with sterile saline solution twice a day for 30 days, then it had a strong anti-inflammatory, wound-healing, and angioprotective effects. This positively affected the course of reparative process in the conjunctiva and cornea complicated by nonclosing of the eyelids. It was also found that drug No. 5 in the tested dose promoted the stimulation of reparative processes in the conjunctiva and cornea, clinically manifesting itself in accelerating the recovery of defects in the anterior epithelium and corneal stroma, and in reducing both frequency of formation of deep corneal defects and severity of inflammatory response and vascularization. There was a slowdown in the formation of corneal opacities, a decrease in the amount and appearance of a more liquid mucous discharge of the conjunctiva compared to the control. It was also demonstrated in the stated model of DES that drug No. 5 in the test dose had a pronounced pharmacological effect, contributing to a faster recovery of damage to the superficial epithelium and stroma of the cornea, anterior and posterior chambers of the eye, the vascular membrane and retina as well as goblet cells of the conjunctiva.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.